Hunton Andrews Kurth Continues Global Energy Team Expansion in London
11.12.2024 10:00:00 CET | Business Wire | Press release
One Year of Sustained Local Growth Includes More Than Two Dozen Lawyers
Hunton Andrews Kurth LLP continues to expand in London with the addition of nearly a dozen highly regarded energy and project finance lawyers.
Partners Charles Morrison, Dimitri Papaefstratiou, Simon Collier, Harry Brunt, Counsel Joseph Lam, and ConsultantGrant Henderson, along with five associates, have joined the firm from Ernst & Young’s legal services arm, EY Law. The team focuses on transactions in various energy sectors, such as oil and gas, renewable and thermal power, as well as emerging technologies of carbon capture, hydrogen and energy storage.
“The addition of these distinguished lawyers underscores our commitment to maintaining our position as a leading adviser to the global energy industry,” said Hunton Andrews Kurth Managing Partner Sam Danon. “The team aligns well with our international growth strategy, which is focused on ensuring that we’ve achieved critical mass in key practices, in core industry focus areas and in geographies where client demand is strong.”
“Energy sector activity remains incredibly robust, driven by the need for renewable and alternative solutions in support of the energy transition as well as the need for infrastructure and traditional resource development in emerging and mature economies,” added Jeff Schroeder, head of Hunton Andrews Kurth’s energy and infrastructure team. “We are particularly excited about the team’s capabilities to grow the pipeline of complex, cross-border energy projects and adding depth to our global energy practice.”
In support of its international growth strategy, since August 2023, Hunton Andrews Kurth has added more than two dozen lawyers to its London office. Most recently, finance Partners Alan Cunningham and Richard Skipper joined the firm from EY Law. In September, the firm added project finance Partners Ayesha Waheed and Seyfi Can Kandemir. Last year, Hunton Andrews Kurth welcomed to Londoncorporate energy Partner Philip Mace and energy and infrastructure disputes Partners Maurice Kentonand David Hesse, Counsel Edward Hamiltonand Special Counsel Simon Schooling, who collectively are leading members of the firm’s international arbitration team.
“Our energy-focused corporate and disputes teams in London have experienced tremendous growth over the past year, expanding our reach throughout Europe, the Middle East and Africa,” said Ferdinand Calice, managing partner of Hunton Andrews Kurth’s London office. “We are pleased to welcome our newest colleagues to the firm.”
About Hunton Andrews Kurth’s Energy and Infrastructure Team
Hunton Andrews Kurth’s global energy and infrastructure lawyers assist clients in bringing some of the world’s largest and most complex projects to market. Our team provides concept-to-close advice on the development and financing of capital-intensive projects. We represent sponsors, lenders, investors, governments, and other project participants operating in virtually every segment of the energy industry and infrastructure industry. Our projects attorneys have handled transactions in more than 75 countries, with market leading strengths in project finance, agency finance, commercial nuclear power, U.S. energy tax credits, subsea fiber-optic networks, and utility capital markets, among many others.
About Hunton Andrews Kurth LLP
For more than 120 years, Hunton Andrews Kurth has served clients across the globe with a collaborative and purposeful approach. With offices strategically located in the United States and around the world, the firm is known for its strength in the energy, financial services, real estate, and retail and consumer products industries, as well as its considerable depth across numerous practice areas. Hunton Andrews Kurth fosters a strong culture built upon an unwavering commitment to its clients, colleagues, and communities. To learn more, please visit huntonak.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241211423314/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom